The antiviral drug market faces changes: Oseltamivir may be temporarily taken off the shelves.

In the past, oseltamivir, which used to dominate the market for anti-influenza drugs, has encountered a controversy. Recently, the Zhejiang Provincial Medical Insurance Bureau announced a drug price adjustment notice, including oseltamivir phosphate capsules produced by companies such as Natco Pharma Limited, Dongyang Guangchangjiang Pharmaceutical, Chengdu Betel, Pule Pharmaceutical, and Luoxin Pharmaceutical, all facing price adjustments or temporary suspension from the network. The listed "Kewei" brand oseltamivir phosphate capsules, one of the flagship products of Dongyang Guangchangjiang Pharmaceutical, are one of the varieties affected. Although the specific price adjustment range was not disclosed, the Zhejiang Provincial Medical Insurance Bureau specifically mentioned "involving price complaints." Prior to the joint procurement, public information showed that the price of oseltamivir phosphate capsules was over a hundred yuan. In 2022, oseltamivir phosphate capsules were included in the seventh batch of national joint procurement, with the lowest selected price per pill being less than 1 yuan. The parent company of Dongyang Guangchangjiang Pharmaceutical, Guangdong Dongyang Guang Pharmaceutical Co., Ltd., quoted 0.99 yuan per tablet, a decrease of up to 92% compared to the highest effective declared price of 13.01 yuan for the same specification.